FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380990722> ?p ?o ?g. }

• W4380990722 abstract "Abstract Background The number of pneumocystis pneumonia (PCP) cases is increasing in immunocompromised patients without human immunodeficiency virus infection (HIV), causing serious morbidity with high mortality. Trimethoprim/sulfamethoxazole (TMP/SMZ) monotherapy has limited effectiveness in the treatment of PCP. Clinical data on whether initial caspofungin plus TMP/SMZ for this disease is superior to monotherapy in non-HIV-infected patients are limited. We aimed to compare the clinical effectiveness of these regimens for severe PCP in non-HIV patients. Methods A retrospective study reviewed 104 non-HIV-infected patients with confirmed PCP in the intensive care unit between January 2016 and December 2021. Eleven patients were excluded from the study because TMP/SMZ could not be used due to severe hematologic disorders or clinical data were missing. All enrolled patients were divided into three groups according to different treatment strategies: Group 1 received TMP/SMZ monotherapy, Group 2 received caspofungin combined with TMP/SMZ as first-line therapy, and Group 3 initially received TMP/SMZ monotherapy and later received caspofungin as salvage therapy. The clinical characteristics and outcomes were compared among the groups. Results A total of 93 patients met the criteria. The overall positive response rate of anti-PCP treatment was 58.06%, and the overall 90-day all-cause mortality rate was 49.46%. The median APACHE II score was 21.44. The concurrent infection rate was 74.19%, among whom 15.05% (n = 14) of those patients had pulmonary aspergillosis, 21.05% (n = 20) had bacteremia, and 23.65% (n = 22) had CMV infections. The patients who received initial caspofungin combination with TMP/SMZ had the best positive response rate (76.74%) compared to others ( p = 0.001). Furthermore, the group that received initial caspofungin combined with TMP/SMZ had a 90-day all-cause mortality rate (39.53%) that was significantly different from that of the shift group (65.51%, p = 0.024), but this rate showed no statistically significant difference compared with that in the monotherapy group (48.62%, p = 0.322). None of the patients had serious adverse events from caspofungin therapy. Conclusions For non-HIV-infected patients with severe PCP, initial combination therapy with caspofungin and TMP/SMZ is a promising first-line treatment option compared with TMP/SMZ monotherapy and combination therapy as salvage therapy." @default.
• W4380990722 created "2023-06-17" @default.
• W4380990722 creator A5003209877 @default.
• W4380990722 creator A5003268354 @default.
• W4380990722 creator A5040719614 @default.
• W4380990722 creator A5053505858 @default.
• W4380990722 creator A5059658106 @default.
• W4380990722 creator A5073502482 @default.
• W4380990722 date "2023-06-16" @default.
• W4380990722 modified "2023-10-08" @default.
• W4380990722 title "Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection" @default.
• W4380990722 cites W1839482599 @default.
• W4380990722 cites W1911541991 @default.
• W4380990722 cites W1966138936 @default.
• W4380990722 cites W1968696159 @default.
• W4380990722 cites W1987157628 @default.
• W4380990722 cites W1987889643 @default.
• W4380990722 cites W1993349281 @default.
• W4380990722 cites W2011525824 @default.
• W4380990722 cites W2018502636 @default.
• W4380990722 cites W2028032483 @default.
• W4380990722 cites W2049219987 @default.
• W4380990722 cites W2071112130 @default.
• W4380990722 cites W2085868734 @default.
• W4380990722 cites W2097770692 @default.
• W4380990722 cites W2114359819 @default.
• W4380990722 cites W2121155577 @default.
• W4380990722 cites W2129246503 @default.
• W4380990722 cites W2132791599 @default.
• W4380990722 cites W2135138895 @default.
• W4380990722 cites W2143794058 @default.
• W4380990722 cites W2144185070 @default.
• W4380990722 cites W2146457330 @default.
• W4380990722 cites W2170896054 @default.
• W4380990722 cites W2219805094 @default.
• W4380990722 cites W2338138381 @default.
• W4380990722 cites W2351199759 @default.
• W4380990722 cites W2755688179 @default.
• W4380990722 cites W2912839354 @default.
• W4380990722 cites W2951442278 @default.
• W4380990722 cites W2969984490 @default.
• W4380990722 cites W2979987114 @default.
• W4380990722 cites W3011730997 @default.
• W4380990722 cites W3106923286 @default.
• W4380990722 cites W4282944960 @default.
• W4380990722 doi "https://doi.org/10.1186/s12879-023-08372-z" @default.
• W4380990722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37328748" @default.
• W4380990722 hasPublicationYear "2023" @default.
• W4380990722 type Work @default.
• W4380990722 citedByCount "0" @default.
• W4380990722 crossrefType "journal-article" @default.
• W4380990722 hasAuthorship W4380990722A5003209877 @default.
• W4380990722 hasAuthorship W4380990722A5003268354 @default.
• W4380990722 hasAuthorship W4380990722A5040719614 @default.
• W4380990722 hasAuthorship W4380990722A5053505858 @default.
• W4380990722 hasAuthorship W4380990722A5059658106 @default.
• W4380990722 hasAuthorship W4380990722A5073502482 @default.
• W4380990722 hasBestOaLocation W43809907221 @default.
• W4380990722 hasConcept C126322002 @default.
• W4380990722 hasConcept C141071460 @default.
• W4380990722 hasConcept C16005928 @default.
• W4380990722 hasConcept C167135981 @default.
• W4380990722 hasConcept C179755657 @default.
• W4380990722 hasConcept C190139176 @default.
• W4380990722 hasConcept C203014093 @default.
• W4380990722 hasConcept C2777160144 @default.
• W4380990722 hasConcept C2777559004 @default.
• W4380990722 hasConcept C2777914695 @default.
• W4380990722 hasConcept C2779425571 @default.
• W4380990722 hasConcept C2779443120 @default.
• W4380990722 hasConcept C2779548794 @default.
• W4380990722 hasConcept C2779629538 @default.
• W4380990722 hasConcept C2780402444 @default.
• W4380990722 hasConcept C2780728791 @default.
• W4380990722 hasConcept C501593827 @default.
• W4380990722 hasConcept C71924100 @default.
• W4380990722 hasConcept C86803240 @default.
• W4380990722 hasConcept C89423630 @default.
• W4380990722 hasConceptScore W4380990722C126322002 @default.
• W4380990722 hasConceptScore W4380990722C141071460 @default.
• W4380990722 hasConceptScore W4380990722C16005928 @default.
• W4380990722 hasConceptScore W4380990722C167135981 @default.
• W4380990722 hasConceptScore W4380990722C179755657 @default.
• W4380990722 hasConceptScore W4380990722C190139176 @default.
• W4380990722 hasConceptScore W4380990722C203014093 @default.
• W4380990722 hasConceptScore W4380990722C2777160144 @default.
• W4380990722 hasConceptScore W4380990722C2777559004 @default.
• W4380990722 hasConceptScore W4380990722C2777914695 @default.
• W4380990722 hasConceptScore W4380990722C2779425571 @default.
• W4380990722 hasConceptScore W4380990722C2779443120 @default.
• W4380990722 hasConceptScore W4380990722C2779548794 @default.
• W4380990722 hasConceptScore W4380990722C2779629538 @default.
• W4380990722 hasConceptScore W4380990722C2780402444 @default.
• W4380990722 hasConceptScore W4380990722C2780728791 @default.
• W4380990722 hasConceptScore W4380990722C501593827 @default.
• W4380990722 hasConceptScore W4380990722C71924100 @default.
• W4380990722 hasConceptScore W4380990722C86803240 @default.
• W4380990722 hasConceptScore W4380990722C89423630 @default.
• W4380990722 hasIssue "1" @default.
• W4380990722 hasLocation W43809907221 @default.

• next